Sugi Predict

Sugi Predict / Compounds / SCHEMBL1035343

SCHEMBL1035343

SCHEMBL1035343

Oc1ccccc1N1CC[N]CC1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 10/20 0.59
▸ HTT P42858 2/20 0.59
▸ RAB9A P51151 2/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ GFER P55789 2/20 0.47
▸ KMT2A Q03164 5/20 0.47
▸ MEN1 O00255 4/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ DRD4 P21917 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ LMNA P02545 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ MAPT P10636 3/20 0.42
▸ DRD2 P14416 1/20 0.42
▸ DRD3 P35462 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ ALOX12 P18054 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4019882 0.84 GAA (0.70) GAAHTTRAB9ANPC1GFER
SCHEMBL11120307 0.84 GAA (0.70) GAAHTTRAB9ANPC1GFER
SCHEMBL3043141 0.80 GAA (0.60) GAAHTTRAB9ANPC1GFER
SCHEMBL1010647 0.80 GAA (0.60) GAAHTTRAB9ANPC1GFER
SCHEMBL1008507 0.78 GAA (0.58) GAAHTTRAB9ANPC1KMT2A
SCHEMBL219341 0.77 ADRB1 (0.59) HTTRAB9AKMT2AMEN1DRD4
SCHEMBL531748 0.75 ADRB1 (0.62) GAAHTTALDH1A1LMNAHPGD
SCHEMBL217611 0.75 ADRB1 (0.60) HTTNPC1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL33868 0.75 GAA (0.55) GAAHTTRAB9ANPC1KMT2A
SCHEMBL1308333 0.75 ADRA2C (0.60) GAAHTTRAB9ANPC1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110337293-A Therapeutic compound 新泽西鲁特格斯州立大学 2019-10-15 — — CN claimed
US-9663464-B2 Carbazole derivatives acting on 5-HT7 receptor KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2017-05-30 — — US claimed
US-20160244408-A1 CARBAZOLE DERIVATIVES ACTING ON 5-HT7 RECEPTOR KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2016-08-25 — — US claimed
JP-4818110-B2 — — 2011-11-16 — — JP claimed
EP-2301928-A1 Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders AstraZeneca AB (SE) 2011-03-30 — — EP claimed
EP-1831173-B1 TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2011-01-26 — — EP claimed
US-7767666-B2 Butyl and butynyl benzyl amine compounds JANSSEN PHARMACEUTICA NV (BE) 2010-08-03 — — US claimed
WO-2010022055-A2 INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2010-02-25 — — WO claimed
US-20090137562-A1 SUBSTITUTED BENZYL AMINE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2009-05-28 — — US claimed
EP-2049473-A2 SUBSTITUTED BENZYL AMINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-22 — — EP claimed
US-20080004258-A1 BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-03 — — US claimed
WO-2008002820-A2 SUBSTITUTED BENZYL AMINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-03 — — WO claimed
US-7304051-B2 Quinoxaline compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-04 — — US claimed
US-7241759-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-10 — — US claimed
WO-2007015064-A1 IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2007-02-08 — — WO claimed
US-20060194837-A1 Tetrahydroisoquinoline compounds JANSSEN PHARMACEUTICA N.V. (BE) 2006-08-31 — — US claimed
EP-1651621-A1 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-03 — — EP claimed
WO-2005016896-A1 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-24 — — WO claimed
US-20050038032-A1 Quinoxaline compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-17 — — US claimed
US-20040224983-A1 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2004-11-11 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004258-A1 BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS HRH3, HNMT, HRH4 GAA 1473/4885HTT 367/4885RAB9A 1609/4885
US-20060194837-A1 Tetrahydroisoquinoline compounds HRH3, HRH4, HRH1 GAA 2323/4885HTT 81/4885RAB9A 1013/4885
US-20090137562-A1 SUBSTITUTED BENZYL AMINE COMPOUNDS HRH3, HNMT, HRH4 GAA 1216/4885HTT 319/4885RAB9A 1073/4885
US-20050038032-A1 Quinoxaline compounds CCKAR, CCKBR, GIPR GAA 1879/4885HTT 1570/4885RAB9A 562/4885
US-20040224983-A1 Benzo[1,2,5]thiadiazole compounds CCKBR, CCKAR, BRSK2 GAA 3387/4885HTT 3165/4885RAB9A 2813/4885
US-20160244408-A1 CARBAZOLE DERIVATIVES ACTING ON 5-HT7 RECEPTOR HTR7, HTR3A, HTR3B GAA 4626/4885HTT 2385/4885RAB9A 2594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.